Full Press Release Details
Teva Reports Third Quarter 2017 Financial Results
JERUSALEM--(BUSINESS WIRE)--November 2, 2017--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended September 30, 2017.
Revenues in the third quarter of 2017 were $5.6 billion, up 1% compared to the third quarter of 2016. Excluding the impact of foreign exchange fluctuations, revenues increased 4%.
Exchange rate differences between the third quarter of 2017 and the third quarter of 2016 reduced revenues by $169 million, GAAP operating income by $32 million and non-GAAP operating income by $17 million.
Adjustments of the exchange rates used for the Venezuelan bolivar resulted in a decrease of $243 million in revenues, a decrease of $25 million in GAAP operating income and a decrease of $15 million in non-GAAP operating income, compared to results in the third quarter of 2016. In light of the political and economic conditions in Venezuela, we exclude the quarterly changes in revenues and operating profit in Venezuela from any discussion of local currency results.
GAAP gross profit was $2.6 billion in the third quarter of 2017, down 6% compared to the third quarter of 2016. GAAP gross profit margin was 47.1% in the third quarter of 2017, compared to 50.4% in the third quarter of 2016. Non-GAAP gross profit was $3.0 billion in the third quarter of 2017, a decline of 12% from the third quarter of 2016. Non-GAAP gross profit margin was 53.0% in the third quarter of 2017, compared to 61.0% in the third quarter of 2016. The decrease in gross profit margin, on both a GAAP and a non-GAAP basis, was the result of lower gross profit and profitability of both our generic medicines and our specialty medicines businesses, as well as the addition of the low-margin Anda distribution business. GAAP results were impacted by lower inventory step-up expenses and lower amortization expenses, which mitigated some of the decrease.
Research and Development (R&D) expenses for the third quarter of 2017 amounted to $545 million, down 18% compared to the third quarter of 2016 due to lower expenditure related both to generic and specialty medicines as well as lower other R&D expenses. R&D expenses excluding equity compensation expenses and other R&D expenses were $381 million, or 6.8% of quarterly revenues in the third quarter of 2017, compared to $406 million, or 7.3%, in the third quarter of 2016. R&D expenses related to our generic medicines segment were $162 million, a decrease of 12% compared to $185 million in the third quarter of 2016, mainly due to portfolio optimization and various efficiency measures. R&D expenses related to our specialty medicines segment were $217 million, a decrease of 5% compared to $228 million in the third quarter of 2016, mainly due to portfolio optimization activities which compensated for the increased expenses related to our late-stage product candidates.
Selling and Marketing (S&M) expenses in the third quarter of 2017 amounted to $860 million, a decrease of 9% compared to the third quarter of 2016. S&M expenses excluding amortization of purchased intangible assets and equity compensation expenses were $805 million, or 14.3% of revenues, in the third quarter of 2017, compared to $889 million, or 16.0% of revenues, in the third quarter of 2016. S&M expenses related to our generic medicines segment were $377 million, a decrease of 11% compared to $423 million in the third quarter of 2016, mainly due to lower expenses in Venezuela following exchange rate adjustments as well as certain efficiency measures, partially offset by the inclusion of the S&M expenses of the Actavis Generics business for a full quarter. S&M expenses related to our specialty medicines segment were $388 million, down 15% compared to $458 million in the third quarter of 2016, mainly due to cost reduction and efficiency measures in our commercial operations, aligning with the life cycle of our product portfolio.
General and Administrative (G&A) expenses in the third quarter of 2017 amounted to $330 million, compared to $310 million in the third quarter of 2016. G&A expenses excluding equity compensation expenses were $318 million in the third quarter of 2017, or 5.7% of quarterly revenues, compared to $304 million, or 5.5% in the third quarter of 2016.
GAAP operating income in the third quarter of 2017 was $378 million, compared to operating income of $765 million in the third quarter of 2016. Non-GAAP operating income in the third quarter of 2017 was $1.5 billion, a decrease of 18% compared to the third quarter of 2016. Non-GAAP operating margin was 26.2% in the third quarter of 2017 compared to 32.2% in the third quarter of 2016.
EBITDA (non-GAAP operating income, which excludes amortization and certain other items, as well as excluding depreciation expenses) was $1.6 billion in the third quarter of 2017, down 16% compared to $1.9 billion in the third quarter of 2016.
GAAP financial expenses for the third quarter of 2017 were $259 million, compared to $150 million in the third quarter of 2016. Non-GAAP financial expenses were $229 million in the third quarter of 2017, compared to $151 million in the third quarter of 2016. The increase in our non-GAAP financial expenses is due mainly to higher expenses related to net foreign exchange losses and financial derivatives, as well as higher interest expenses related to the debt raised to finance the acquisition of Actavis Generics.
GAAP income taxes for the third quarter of 2017 amounted to a benefit of $494 million. In the third quarter of 2016, income taxes amounted to $207 million, or 34% on pre-tax income of $615 million. Non-GAAP income taxes for the third quarter of 2017 amounted to $135 million on pre-tax non-GAAP income of $1.2 billion, for a quarterly tax rate of 11%. Non-GAAP income taxes in the third quarter of 2016 amounted to $261 million on pre-tax non-GAAP income of $1.6 billion, for a quarterly tax rate of 16%.
We expect our annual non-GAAP tax rate for 2017 to be 15%, lower than our previous estimates. This is due to changes in the geographical mix of income we expect to generate this year. Our non-GAAP tax rate for 2016 was 17%.
GAAP net income attributable to ordinary shareholders and GAAP diluted EPS were $530 million and $0.52, respectively, in the third quarter of 2017, compared to $348 million and $0.35, respectively, in the third quarter of 2016. Non-GAAP net income attributable to ordinary shareholders for calculating diluted EPS and non-GAAP diluted EPS were $1.0 billion and $1.00, respectively, in the third quarter of 2017, compared to $1.4 billion and $1.31 in the third quarter of 2016.
For the third quarter of 2017, the weighted average outstanding shares for the fully diluted earnings per share calculation on both a GAAP and a non-GAAP basis was 1,017 million. For the third quarter of 2016, this was 984 million shares on a GAAP basis, and 1,044 million shares on a non-GAAP basis. For the three months ended September 30, 2017, the mandatory convertible preferred shares amounting to 59.4 million weighted average shares, had an anti-dilutive effect on earnings per share and were therefore excluded from the outstanding shares calculation.
As of September 30, 2017, the fully diluted share count for calculating Teva's market capitalization was approximately 1,083 million shares.
Non-GAAP information : Net non-GAAP adjustments in the third quarter of 2017 were $482 million. Non-GAAP net income and non-GAAP EPS for the quarter were adjusted to exclude the following items:
Teva believes that excluding such items facilitates investors' understanding of its business. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP figures. Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.
Cash flow from operations generated during the third quarter of 2017 was $1.1 billion, compared to $1.5 billion in the third quarter of 2016. The decrease was mainly due to the impact of changes in working capital which increased by $0.3 billion.
Free cash flow, excluding net capital expenditures, was $0.9 billion, compared to $1.2 billion in the third quarter of 2016.
Total balance sheet assets amounted to $86.1 billion as of September 30, 2017, compared to $86.4 billion as of June 30, 2017.
As of September 30, 2017, our debt was $34.7 billion, compared to $35.1 billion at June 30, 2017. The decrease was mainly due to $0.6 billion of debt repayments of our 5 year term loan, our revolving credit facility and other short term loans, partially offset by foreign exchange fluctuations of $0.2 billion. The portion of total debt classified as short-term at September 30, 2017 was 8%.
Total shareholders' equity was $30.3 billion as of September 30, 2017, compared to $29.6 billion as of June 30, 2017.
Segment Results for the Third Quarter 2017
Beginning in the fourth quarter of 2016, our OTC business, conducted primarily through PGT, is included in our generic medicines segment. This segment also includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms and our API manufacturing business.
All data presented has been conformed to the new segment structure.
Generic Medicines Segment
| Three Months Ended September 30, | ||||||||||
| 2017 | 2016 | |||||||||
| U.S. $ in millions / % of Segment Revenues | ||||||||||
| Revenues | $ | 3,007 | 100.0% | $ | 3,259 | 100.0% | ||||
| Gross profit | 1,158 | 38.5% | 1,590 | 48.8% | ||||||
| R&D expenses | 162 | 5.4% | 185 | 5.7% | ||||||
| S&M expenses | 377 | 12.5% | 423 | 13.0% | ||||||
| Segment profit* | $ | 619 | 20.6% | $ | 982 | 30.1% |
| __________ |
| * Segment profit consists of gross profit for the segment, less R&D and S&M expenses related to the segment. Segment profit does not include G&A expenses, amortization and certain other items. |
Generic Medicines Revenues
Generic medicines revenues in the third quarter of 2017 were $3.0 billion, a decrease of 8% compared to the third quarter of 2016.
Generic revenues consisted of:
Generic medicines revenues comprised 54% of our total revenues in the quarter, compared to 59% in the third quarter of 2016.
Generic Medicines Gross Profit
Gross profit of our generic medicines segment in the third quarter of 2017 was $1.2 billion, a decrease of 27% compared to the third quarter of 2016. The lower gross profit was mainly due to higher production expenses, market dynamics in the United States and lower revenues in Venezuela following the currency devaluation.
Gross profit margin for our generic medicines segment in the third quarter of 2017 decreased to 38.5% from 48.8% in the third quarter of 2016.
The decrease in gross profit margin was due to lower profitability in our U.S. and ROW markets, partially offset by improved profitability of our European markets.
Generic Medicines Profit
Our generic medicines segment generated profit of $619 million in the third quarter of 2017, a decrease of 37% compared to the third quarter of 2016. Generic medicines profitability as a percentage of generic medicines revenues was 20.6% in the third quarter of 2017, down from 30.1% in the third quarter of 2016.
Specialty Medicines Segment
| Three Months Ended September 30, | ||||||||||
| 2017 | 2016 | |||||||||
| U.S. $ in millions / % of Segment Revenues | ||||||||||
| Revenues | $ | 2,034 | 100.0% | $ | 2,048 | 100.0% | ||||
| Gross profit | 1,757 | 86.4% | 1,783 | 87.1% | ||||||
| R&D expenses | 217 | 10.7% | 228 | 11.1% | ||||||
| S&M expenses | 388 | 19.1% | 458 | 22.4% | ||||||
| Segment profit* | $ | 1,152 | 56.6% | $ | 1,097 | 53.6% |
| __________ |
| * Segment profit consists of gross profit for the segment, less R&D and S&M expenses related to the segment. Segment profit does not include G&A expenses, amortization and certain other items. |
Specialty Medicines Revenues
Specialty medicines revenues in the third quarter of 2017 were $2.0 billion, down 1% compared to the third quarter of 2016. U.S. specialty medicines revenues were $1.5 billion, down 4% compared to the third quarter of 2016. European specialty medicines revenues were $447 million, an increase of 10%, or 5% in local currency terms, compared to the third quarter of 2016. ROW specialty revenues were $94 million, up 12%, in both dollar and local currency terms, compared to the third quarter of 2016.
Specialty medicines revenues comprised 36% of our total revenues in the quarter, compared to 37% in the third quarter of 2016.
The decrease in specialty medicines revenues compared to the third quarter of 2016 was primarily due to lower sales of our CNS products, which were largely offset by higher sales in all other therapeutic areas.
The following table presents revenues by therapeutic area and key products for our specialty medicines segment for the three months ended September 30, 2017 and 2016:
| Three Months Ended September 30, | Change | |||||||
| 2017 | 2016 | 2017 - 2016 | ||||||
| U.S. $ in millions | ||||||||
| CNS | $ | 1,146 | $ | 1,302 | (12%) | |||
| Copaxone | 987 | 1,061 | (7%) | |||||
| Azilect | 36 | 101 | (64%) | |||||
| Nuvigil | 21 | 21 | 0% | |||||
| Respiratory | 351 | 270 | 30% | |||||
| ProAir | 155 | 118 | 31% | |||||
| QVAR | 95 | 96 | (1%) | |||||
| Oncology | 302 | 269 | 12% | |||||
| Treanda and Bendeka | 181 | 149 | 21% | |||||
| Women's Health | 119 | 109 | 9% | |||||
| Other Specialty | 116 | 98 | 18% | |||||
| Total Specialty Medicines | $ | 2,034 | $ | 2,048 | (1%) |
Global revenues of Copaxone (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, were $1.0 billion, a decrease of 7% compared to the third quarter of 2016.
In October 2017, the FDA approved a generic version of Copaxone 40 mg /mL and an additional generic version of Copaxone 20 mg/mL. A generic version of Copaxone 40 mg /mL was launched in the U.S. market. In the EU, a hybrid version of Copaxone 40 mg/mL was approved.
Copaxone revenues in the United States, were $802 million, a decrease of 8% compared to the third quarter of 2016, due to lower volumes of Copaxone 20 mg/mL, negative net pricing effects, mainly as a result of an increase in managed care rebate accruals for inventory in the channel following the FDA approvals for additional generic competition, partially offset by a price increase of 7.9% in January 2017 for both the 20 mg/mL and 40 mg/mL versions. At the end of the third quarter of 2017, according to September 2017 IMS data, our U.S. market shares for the Copaxone products in terms of new and total prescriptions were 25.6% and 28.7%, respectively. Copaxone 40 mg/mL accounted for over 85% of total Copaxone prescriptions in the U.S.
Copaxone revenues outside the United States were $185 million, down 1%, compared to the third quarter of 2016. Over 75% of European Copaxone prescriptions are now filled with the 40 mg/mL version.
Our global Azilect revenues were $36 million, a decrease of 64% compared to the third quarter of 2016 following the introduction of generic competition to Azilect in the United States in 2017.
Revenues of our respiratory products were $351 million, up 30% compared to the third quarter of 2016 mainly due to higher sales of ProAir as well as the launches of Braltus and Cinqair /Cinqaero . ProAir revenues in the third quarter of 2017 were $155 million, up 31% compared to the third quarter of 2016, mainly due to higher positive net pricing effects and higher volumes sold. QVAR global revenues were $95 million in the third quarter of 2017, down 1% compared to the third quarter of 2016.
Revenues of our oncology products were $302 million in the third quarter of 2017, up 12% compared to the third quarter of 2016. Combined revenues of Treanda and Bendeka were $181 million, up 21% compared to the third quarter of 2016, mainly due to higher volumes sold related to timing of purchases.
During September 2017, we entered into several agreements to sell certain non-core specialty products, including our global women's health business. On November 1, we announced the completion of the Paragard divestiture to CooperSurgical. The remaining transactions are expected to close during the remainder of 2017 and in 2018.
Specialty Medicines Gross Profit
Gross profit of our specialty medicines segment was $1.8 billion, a decrease of $26 million compared to the third quarter of 2016. Gross profit margin for our specialty medicines segment in the third quarter of 2017 was 86.4%, compared to 87.1% in the third quarter of 2016.
Specialty Medicines Profit
Our specialty medicines segment profit was $1.2 billion in the third quarter of 2017, up 5% compared to the third quarter of 2016.
Specialty medicines profit as a percentage of segment revenues was 56.6% in the third quarter of 2017, compared to 53.6% in the third quarter of 2016.
The increase in profit and profitability was driven by lower S&M and R&D expenses, partially offset by lower gross profit.
The following tables present details of our multiple sclerosis franchise and of our other specialty medicines for the three months ended September 30, 2017 and 2016:
| Multiple Sclerosis | ||||||||||
| Three months ended September 30, | ||||||||||
| 2017 | 2016 | |||||||||
| U.S.$ in millions / % of MS Revenues | ||||||||||
| Revenues | $ | 987 | 100.0% | $ | 1,061 | 100.0% | ||||
| Gross profit | 906 | 91.8% | 982 | 92.6% | ||||||
| R&D expenses | 16 | 1.6% | 20 | 1.9% | ||||||
| S&M expenses | 64 | 6.5% | 76 | 7.2% | ||||||
| MS profit | $ | 826 | 83.7% | $ | 886 | 83.5% | ||||
| Other Specialty | ||||||||||
| Three months ended September 30, | ||||||||||
| 2017 | 2016 | |||||||||
| U.S.$ in millions / % of Other Specialty Revenues | ||||||||||
| Revenues | $ | 1,047 | 100.0% | $ | 987 | 100.0% | ||||
| Gross profit | 851 | 81.3% | 801 | 81.2% | ||||||
| R&D expenses | 201 | 19.2% | 208 | 21.1% | ||||||
| S&M expenses | 324 | 31.0% | 382 | 38.7% | ||||||
| Other Specialty profit | $ | 326 | 31.1% | $ | 211 | 21.4% |
Other Activities
Other revenues (primarily sales of third-party products for which we act as distributor, mostly in the United States via Anda, contract manufacturing services related to products divested in connection with the Actavis Generics acquisition and other miscellaneous items) were $569 million in the third quarter of 2017, compared to $256 million, in the third quarter of 2016. The increase was mainly related to the inclusion of Anda's revenues beginning in the fourth quarter of 2016.
Revenues from these other activities comprised 10% of our total revenues in the quarter, compared to 5% in the third quarter of 2016.
Updated 2017 Financial Outlook
| FY 2017 | Implied Q4 2017 Outlook | |||
| Revenues | $22.2-22.3 billion (previously $22.8-23.2 billion) | $5.3-5.4 billion | ||
| Non-GAAP EPS | $3.77-3.87 (previously $4.30-4.50) | $0.70-0.80 | ||
| Cash flow from operations | $3.15-3.3 billion (previously $4.4-4.6 billion) | $0.85-1.0 billion |
Our 2017 financial outlook was lowered to reflect the following:
These estimates reflect management's current expectations for Teva's performance in 2017. Actual results may vary, whether as a result of exchange rate differences, market conditions or other factors. In addition, the non-GAAP measures exclude the amortization of purchased intangible assets, costs related to certain regulatory actions, inventory step-up, legal settlements and reserves, impairments and related tax effects.
On October 31, 2017, the Board of Directors declared a cash dividend of $0.085 per ordinary share for the third quarter of 2017. For holders of our ordinary shares that are traded on the Tel Aviv Stock Exchange, the dividend will be converted into new Israeli shekels based on the official exchange rate as of November 2, 2017. The record date will be November 28, 2017, and the payment date will be December 12, 2017. Tax will be withheld at a rate of 15%.
On October 31, 2017, the Board of Directors also declared a cash dividend of $17.50 per Mandatory Convertible Preferred Share for the third quarter of 2017. The record date will be December 1, 2017 and the payment date will be December 15, 2017. Tax will be withheld at a rate of 15%.
Conference Call
Teva will host a conference call and live webcast along with a slide presentation on Thursday, November 2, 2017 at 8:00 a.m. ET to discuss its third quarter 2017 results and overall business environment. A question & answer session will follow.
In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-869-2321; Canada 1-866-766-8269 or International +44(0) 203 0095710; passcode: 91932782. For a list of other international toll-free numbers, click here.
A live webcast of the call will also be available on Teva's website at: www.ir.tevapharm.com . Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until November 30, 2017, 9:00 a.m. ET by calling United States 1-866-247-4222; Canada 1-866-878-9237 or International +44(0) 1452550000; passcode: 91932782.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com .